comparemela.com

Latest Breaking News On - News ratings for oramed pharmaceuticals daily - Page 1 : comparemela.com

Q3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Reduced by Analyst

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) – Equities research analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for shares of Oramed Pharmaceuticals in a research note issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.04) per share for the quarter, […]

Hedge-funds-weigh-in-on-oramed-pharmaceuticals
Algert-global
News-ratings-for-oramed-pharmaceuticals-daily
Oramed-pharmaceuticals-inc
Oramed-pharmaceuticals-stock-performance
Rathbones-group
Nasdaq
Oramed-pharmaceuticals
Ew-advisory-services
Barclays-plc
Capital-management

HC Wainwright Weighs in on Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) – Analysts at HC Wainwright decreased their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a research report issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings of ($0.04) per share for the quarter, down from […]

Capital-management
Oramed-pharmaceuticals
News-ratings-for-oramed-pharmaceuticals-daily
Murchinson-ltd
Oramed-pharmaceuticals-company-profile
Oramed-pharmaceuticals-stock
Virtu-financial
Nasdaq
Rathbones-group
Hedge-funds-weigh-in-on-oramed-pharmaceuticals
Oramed-pharmaceuticals-inc

HC Wainwright Reiterates Neutral Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)

HC Wainwright Reiterates Neutral Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Oramed-pharmaceuticals-trading
Ew-advisory-services
Oramed-pharmaceuticals-inc
Institutional-trading-of-oramed-pharmaceuticals
Algert-global
Barclays-plc
News-ratings-for-oramed-pharmaceuticals-daily
Virtu-financial
Oramed-pharmaceuticals-company-profile
Oramed-pharmaceuticals
Free-report

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200 Day Moving Average of $2.48

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.48 and traded as low as $2.25. Oramed Pharmaceuticals shares last traded at $2.34, with a volume of 44,022 shares. Oramed Pharmaceuticals […]

News-ratings-for-oramed-pharmaceuticals-daily
Oramed-pharmaceuticals-inc
Oramed-pharmaceuticals-price-performance
Nasdaq
Algert-global
Barclays-plc
Oramed-pharmaceuticals
Capital-management
N-ew-advisory-services
Rathbones-group
Institutional-investors-weigh-in-on-oramed-pharmaceuticals

Rathbones Group PLC Acquires Shares of 289,803 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Rathbones Group PLC bought a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 289,803 shares of the biotechnology company’s stock, valued at approximately $756,000. Rathbones Group PLC owned approximately 0.72% […]

Barclays-plc
Ew-advisory-services
News-ratings-for-oramed-pharmaceuticals-daily
Oramed-pharmaceuticals-inc
Quarter-for-oramed-pharmaceuticals
Nasdaq
Exchange-commission
Invesco-ltd
Tower-research-capital
Schonfeld-strategic-advisors
Oramed-pharmaceuticals

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.